Danielle Watson - Heart Test CFO Treasurer
HSCS Stock | USD 2.67 0.05 1.91% |
Insider
Danielle Watson is CFO Treasurer of Heart Test Laboratories
Age | 42 |
Address | 550 Reserve Street, Southlake, TX, United States, 76092 |
Phone | 682-237-7781 |
Web | https://heartsciences.com |
Heart Test Management Efficiency
The company has return on total asset (ROA) of (0.8169) % which means that it has lost $0.8169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6929) %, meaning that it created substantial loss on money invested by shareholders. Heart Test's management efficiency ratios could be used to measure how well Heart Test manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.88 in 2024. Return On Capital Employed is likely to drop to -0.85 in 2024. At this time, Heart Test's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 217.5 K in 2024, whereas Intangible Assets are likely to drop slightly above 1.3 M in 2024.Similar Executives
Showing other executives | INSIDER Age | ||
Christopher Yamamoto | Bioventus | N/A | |
Sanjay Ahuja | Tivic Health Systems | N/A | |
Miguel BeltranDelgado | Bioventus | N/A | |
Richard Ginn | Tenon Medical | 58 | |
Katherine Tweden | ReShape Lifesciences | 63 | |
William MD | Nuwellis | N/A | |
Kenneth Reali | Bioventus | 58 | |
Kevin Vance | Bluejay Diagnostics | 66 | |
Rony Aloni | Inspira Technologies Oxy | N/A | |
Jennifer Ernst | Tivic Health Systems | 56 | |
Laurent Duhoux | Nuwellis | N/A | |
Kenneth CPA | Bluejay Diagnostics | 44 | |
Mark Knudson | ReShape Lifesciences | 75 | |
Shunichi Kuroda | Bone Biologics Corp | N/A | |
DVM DVM | ReShape Lifesciences | N/A | |
Mark Feinberg | Bluejay Diagnostics | N/A | |
Ryan Sabia | Tivic Health Systems | 37 | |
Mark MD | Bluejay Diagnostics | N/A | |
Anthony James | Bioventus | N/A | |
Blake Gurfein | Tivic Health Systems | 40 | |
Rob Scott | Nuwellis | N/A |
Management Performance
Return On Equity | -2.69 | ||||
Return On Asset | -0.82 |
Heart Test Laboratories Management Team
Elected by the shareholders, the Heart Test's board of directors comprises two types of representatives: Heart Test inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heart. The board's role is to monitor Heart Test's management team and ensure that shareholders' interests are well served. Heart Test's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heart Test's outside directors are responsible for providing unbiased perspectives on the board's policies.
Danielle Watson, CFO Treasurer | ||
Andrew Simpson, President CEO | ||
Mark Hilz, Secretary COO |
Heart Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heart Test a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -2.69 | ||||
Return On Asset | -0.82 | ||||
Operating Margin | (379.07) % | ||||
Current Valuation | (887.44 K) | ||||
Shares Outstanding | 913.82 K | ||||
Shares Owned By Insiders | 10.64 % | ||||
Shares Owned By Institutions | 1.42 % | ||||
Number Of Shares Shorted | 23.08 K | ||||
Price To Book | 0.41 X | ||||
Price To Sales | 131.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.